Details of the Drug Reposition

General Information of This Drug (ID: DM30SGU)

• Drug Name: Simvastatin (DM30SGU)
• Synonyms: Cholestat; Coledis; Colemin; Corolin; Denan; Labistatin; Lipex; Lipovas; Lodales; Medipo; Nivelipol; Pantok; Rendapid; Simovil; Simvastatina; Simvastatine; Simvastatinum; Sinvacor; Sivastin; Synvinolin; Vasotenal; Zocor; Zocord; Simvast CR; Simvastatina [Spanish]; Simvastatine [French]; Simvastatinum [Latin]; MK 0733; MK 733; MK733; TNP00259; DRG-0320; KS-1113; L 644128-000U; MK-0733; MK-733; Simcard (TN); Simlup (TN); Simvacor (TN); Simvastatin & Primycin; Simvastatin, Compactin; Zocor (TN); Simvastatin [USAN:INN:BAN]; Simvastatin (JAN/USP/INN); Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
• Therapeutic Class: Anticholesteremic Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

11 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Prostate carcinoma	DISMJPLE	N.A.	Approved	[1]
Hyperlipidemia, familial combined, LPL related	DISL1CE3	N.A.	Approved	[1]
Type-1/2 diabetes	DISIUHAP	5A10-5A11	Approved	[1]
Hyperlipidemia	DIS61J3S	5C80.Z	Approved	[1]
Primary hypercholesterolemia	DIS74LB6	5C80.00	Approved	[1]
Depression	DIS3XJ69	6A70-6A7Z	Approved	[1]
Coronary heart disease	DIS5OIP1	BA80.Z	Approved	[1]
Atherosclerosis	DISMN9J3	BD40	Approved	[1]
Cystic fibrosis	DIS2OK1Q	CA25	Approved	[1]
Pneumonia	DIS8EF3M	CA40	Approved	[1]
Rhinitis	DISKLMN7	FA20	Approved	[1]

1 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypoalphalipoproteinemia	DISZFMB5	N.A.	Withdrawn	[2]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
High blood pressure	DISY2OHH	BA00	Discontinued in Phase 2	[3]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Stroke	DISX6UHX	8B20	Investigative	[1]

References

• [1] Simvastatin FDA Label
• [2] Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
• [3] Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents